Abstract
Pregabalin and gabapentin, two α 2-delta ligands, have demonstrated efficacy in neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). However, pregabalin has nonsaturable absorption at clinically relevant doses, resulting in linear pharmacokinetics and a more predictable exposure compared to gabapentin. Our objective was to compare the attainment of labeled minimally effective dose levels among new users of pregabalin (≥150 mg/day in DPN and PHN) or gabapentin (≥1800 mg/day in PHN).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
